VOL 1 | ISSUE 1

Multiple Myeloma™ UPDATE

Conversations with Oncology Investigators

Bridging the Gap between Research and Patient Care

FACULTY INTERVIEWS

Edward A Stadtmauer, MD
Sarah A Holstein, MD, PhD
Paul G Richardson, MD
Shaji K Kumar, MD

EDITOR

Neil Love, MD

CONTENTS

1 Audio CD

CME Certified

Multiple Myeloma™ UPDATE

Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com
For CME/CNE Information	Email: CE@ResearchToPractice.com

Multiple Myeloma Update
A Continuing Medical Education Audio Series

OVERVIEW OF ACTIVITY

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 12% of all hematologic cancers and carries with it one of the worst death to new cases ratios. Although MM only represented 1.8% of all new cancer cases diagnosed in the United States in 2017, practicing clinicians would be hard pressed to identify another area of oncology in which the research database — and available treatments — has evolved more rapidly over the past decade. In addition to significantly altering the natural history of MM, novel agents, including proteasome inhibitors, immunomodulatory agents and BTK inhibitors, have contributed to recent treatment gains for 2 related blood disorders — Waldenström macroglobulinemia (WM) and amyloidosis. Featuring the latest research developments along with expert perspectives, this CME activity will deliver to community-based oncology clinicians highly applicable, current clinical information delving into the individualized and multifaceted management of these disorders.

LEARNING OBJECTIVES

- Use patient and disease characteristics, including cytogenetic profile, to customize induction and maintenance therapeutic approaches in the transplant and nontransplant settings.
- Consider available research data and other clinical factors in the best-practice selection, sequencing and combination of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory MM.
- Design and implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies to support quality of life and continuation of treatment.
- Develop an evidence-based algorithm for the use of stem cell transplantation, chemotherapy and/or novel targeted agents for the management of amyloidosis.
- Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for WM requiring active treatment.
- Develop risk-adapted treatment plans for patients with smoldering MM, considering the roles of observation and active treatment.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Penn State College of Medicine designates this enduring material for a maximum of 4.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio tracks, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at **ResearchToPractice.com/MMUpdate118/CME**. A complete list of supporting references may also be accessed at **ResearchToPractice.com/MMUpdate118**. The corresponding video program is available as an alternative at **ResearchToPractice.com/MMUpdate118/Video**.

This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.

Release date: February 1, 2018; Expiration date: February 1, 2019

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

If you would like to discontinue your complimentary subscription to *Multiple Myeloma Update*, please email us at **Info@ResearchToPractice.com**, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

CME INFORMATION

FACULTY AFFILIATIONS

Edward A Stadtmauer, MD
Professor of Medicine
Leader, Hematologic Malignancies Program; Director, Bone Marrow and Stem Cell Transplant Program
Division of Hematology-Oncology
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Sarah A Holstein, MD, PhD
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute; RJ Corman Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Shaji K Kumar, MD
Professor of Medicine
Consultant
Division of Hematology and Blood and Marrow Transplantation
Mayo Clinic
Rochester, Minnesota

EDITOR

Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Stadtmauer** — Consulting Agreements: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology. **Dr Holstein** — Advisory Committee: Celgene Corporation, Takeda Oncology; Consulting Agreement: Celgene Corporation. **Dr Richardson** — Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Takeda Oncology. **Dr Kumar** — Consulting Agreements: Abbott Laboratories, Amgen Inc, Merck, Takeda Oncology; Contracted Research: Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Merck, Novartis, Sanofi Genzyme, Takeda Oncology.

EDITOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Interview with Edward A Stadtmauer, MD

Tracks 1-12

Track 1	Evolution of B-cell maturation antigen (BCMA) targeting in multiple myeloma (MM)
Track 2	Chimeric antigen receptor (CAR) T-cell therapy-associated cytokine release syndrome and neurotoxicity
Track 3	Clinical management of cytokine release syndrome
Track 4	Durable remissions with BCMA CAR T-cell therapy in relapsed/refractory (R/R) MM
Track 5	Initial efficacy and safety results with BCMA CAR T-cell therapy
Track 6	Feasibility of administering CAR T-cell therapy in a community setting
Track 7	Mechanism of action of monoclonal antibodies; daratumumab-associated infusion-related reactions
Track 8	Subcutaneous delivery of daratumumab
Track 9	**Case:** A 56-year-old man with R/R MM and t(11;14) receives venetoclax/bortezomib/dexamethasone
Track 10	**Case:** A 54-year-old man with R/R MM receives ixazomib/lenalidomide/dexamethasone
Track 11	Treatment approach for patients who experience relapse while receiving post-transplant lenalidomide maintenance therapy
Track 12	**Case:** A 76-year-old man with previously treated Waldenström macroglobulinemia (WM) experiences a prolonged response to ibrutinib

Interview with Sarah A Holstein, MD, PhD

Tracks 1-20

Track 1	**Case:** A 58-year-old man with newly diagnosed high-risk MM experiences a very good partial response and moderate peripheral neuropathy with lenalidomide/bortezomib/dexamethasone (RVd) induction → autologous stem cell transplant (ASCT) but is unwilling to receive bortezomib maintenance therapy because of concerns about further neuropathy
Track 2	Ixazomib as a component of maintenance therapy for high-risk MM
Track 3	Benefits of post-transplant maintenance therapy
Track 4	RVd consolidation and maintenance therapy for high-risk MM
Track 5	Selecting among options for maintenance therapy
Track 6	Ixazomib-associated gastrointestinal toxicity
Track 7	Carfilzomib- versus bortezomib-based induction therapy
Track 8	Duration of lenalidomide maintenance therapy
Track 9	Early versus delayed ASCT after induction therapy for MM
Track 10	Clinical utility of minimal residual disease (MRD) assessment in MM
Track 11	**Case:** A 59-year-old man with R/R MM and high-risk cytogenetics receives pomalidomide/daratumumab/dexamethasone
Track 12	Triplet therapy options for R/R disease
Track 13	Advantages of subcutaneous daratumumab
Track 14	**Case:** A 41-year-old woman presents with lambda light chain MM and bone marrow amyloidosis
Track 15	**Case:** A 72-year-old man develops myelodysplastic syndrome after receiving post-transplant consolidation RVd and subsequently receives multiple lines of therapy for R/R disease

Interview with Dr Holstein (continued)

Track 16	**Case:** A 52-year-old woman initially diagnosed with smoldering MM presents with widespread bone disease
Track 17	Updated IMWG (International Myeloma Working Group) criteria on risk stratification in MM
Track 18	Management of high-risk R/R MM that progresses rapidly on triplet therapy
Track 19	Activity and tolerability of panobinostat in combination with carfilzomib/dexamethasone
Track 20	Status of the Phase III KEYNOTE-183 and 185 trials: Pembrolizumab in combination with an immunomodulatory drug (IMiD) and dexamethasone

Interview with Paul G Richardson, MD

Tracks 1-25

Track 1	Recent therapeutic advances in MM
Track 2	Changing landscape of smoldering MM
Track 3	Impact of cytogenetics on treatment choice
Track 4	Bisphosphonate therapy in MM
Track 5	Role of histone deacetylase inhibitors in the treatment of MM
Track 6	Correlation between CD38 expression levels and response to daratumumab
Track 7	Optimizing the frequency and convenience of daratumumab administration
Track 8	Clinical experience with the investigational anti-CD38 monoclonal antibody isatuximab
Track 9	ICARIA-MM: An ongoing Phase III trial of pomalidomide and dexamethasone with or without isatuximab for R/R MM
Track 10	Sequencing of therapies to achieve optimal outcomes in MM
Track 11	Recognition and management of immune paresis
Track 12	Potential utility of elotuzumab in combination with lenalidomide in the maintenance setting
Track 13	Toxicities associated with long-term single-agent lenalidomide maintenance therapy; management of lenalidomide-associated diarrhea
Track 14	Recent FDA approval of ibrutinib for chronic graft-versus-host disease
Track 15	Potential of ibrutinib-based combinations for R/R MM
Track 16	Activity and side effects of CAR T-cell therapy in MM
Track 17	Promising therapeutic vaccines and antibodies for MM
Track 18	Effectiveness and tolerability of the investigational proteasome inhibitor marizomib for central nervous system MM and malignant glioblastoma
Track 19	Activity of melflufen, a peptidase-activated derivative of melphalan
Track 20	IFM/DFCI 2009 Phase III trial results: RVd with or without ASCT for newly diagnosed MM
Track 21	**Case:** A 70-year-old woman with high-risk MM and bone metastases receives daratumumab on a clinical trial after disease progression on multiple lines of therapy
Track 22	**Case:** A 61-year-old man with R/R MM receives ixazomib/lenalidomide/dexamethasone on a clinical trial
Track 23	**Case:** A 64-year-old man with R/R MM and bone metastases harbors a 13q deletion abnormality
Track 24	Venetoclax for MM with or without t(11;14)
Track 25	Comparison of proteasome inhibitors for MM

Interview with Shaji K Kumar, MD

Tracks 1-26

Track 1	Improving outcomes for newly diagnosed amyloid light chain (AL) amyloidosis
Track 2	Investigational strategies for the treatment of AL amyloidosis; factors predicting organ response
Track 3	Presentation and treatment of localized AL amyloidosis
Track 4	Advances in the treatment of WM
Track 5	Incorporation of ibrutinib into the treatment of WM
Track 6	Guiding principles in the treatment of WM
Track 7	Diagnosis and management of smoldering MM
Track 8	ASCENT Phase II study of carfilzomib/lenalidomide/ dexamethasone and daratumumab with or without ASCT for patients with high-risk smoldering MM
Track 9	MRD testing in MM and its application in clinical trials and practice
Track 10	MRD negativity after induction therapy and prediction of benefit from transplant
Track 11	Importance of risk stratification in the selection of initial therapy for MM
Track 12	Carfilzomib-associated cardiac dysfunction and dyspnea
Track 13	Advances in the treatment of R/R MM
Track 14	Principles guiding the sequencing of therapies for R/R MM
Track 15	Treatment approach for lenalidomide-refractory relapsed MM
Track 16	Incorporating ixazomib into the treatment algorithm for R/R MM
Track 17	ELOQUENT-2 Phase III trial of elotuzumab/lenalidomide and dexamethasone for R/R MM
Track 18	Evaluation of elotuzumab as part of induction and/or maintenance therapy
Track 19	Therapeutic options for patients with disease that is not refractory to lenalidomide or bortezomib or both
Track 20	Choice of proteasome inhibitor in the relapsed setting
Track 22	Options for patients with “double-refractory” MM
Track 23	Venetoclax for patients with heavily pretreated t(11;14) MM
Track 24	PCR-based assay for Bcl-2 and association with response to venetoclax
Track 25	BCMA CAR T-cell therapy in MM
Track 26	Combining immune checkpoint inhibitors with IMiDs
Track 26	ASCT for relapsed MM

Video Program

View the corresponding video interviews with (from left) Drs Stadtmauer, Holstein, Richardson and Kumar by Dr Love at www.ResearchToPractice.com/MMUpdate118/Video

QUESTIONS (PLEASE CIRCLE ANSWER):

1. **Because it is universally expressed on malignant plasma cells, which of the following antigens is an attractive target for CAR T-cell-directed therapy in MM?***
   a. BCMA
   b. CD19
   c. CD33

2. **A study presented at the 2016 ASH Annual Meeting demonstrated that daratumumab _____ safely be administered via subcutaneous injection.***
   a. Could
   b. Could not

3. **Which of the following proteasome inhibitors has demonstrated activity in myeloma affecting the central nervous system?***
   a. Bortezomib
   b. Ixazomib
   c. Carfilzomib
   d. Marizomib

4. **Ibrutinib is FDA approved for the treatment of _____.**
   a. Chronic graft-versus-host disease
   b. WM
   c. Both a and b
   d. Neither a nor b

5. **Infusion-related reactions associated with the administration of daratumumab tend to persist over the course of the patient's treatment.**
   a. True
   b. False

6. **Which of the following side effects is NOT associated with ixazomib therapy?**
   a. Arthralgia
   b. Gastrointestinal toxicity
   c. Peripheral neuropathy
   d. All of the above

7. **Sensitivity to venetoclax for MM has primarily been observed in patients with t(11;14) disease.***
   a. True
   b. False

8. **The Phase III randomized ELOQUENT-2 study evaluating elotuzumab/lenalidomide/dexamethasone versus lenalidomide/dexamethasone _____ a significant improvement in progression-free survival with the addition of elotuzumab for patients with R/R MM.**
   a. Demonstrated
   b. Did not demonstrate

9. **Which of the following categories reflects the mechanism of action of isatuximab?***
   a. Anti-CD38 monoclonal antibody
   b. Anti-PD-1/PD-L1 antibody
   c. IMiD
   d. Proteasome inhibitor

10. **Recent data presented from the Myeloma X and XI trials demonstrated that lenalidomide maintenance therapy improved outcomes for transplant-eligible patients with _____.**
    a. High-risk MM
    b. Standard-risk MM
    c. Both a and b
    d. Neither a nor b

* The content of this question refers to drugs or the use of drugs that have not yet received FDA approval.

EDUCATIONAL ASSESSMENT AND CREDIT FORM

Multiple Myeloma Update — Volume 1, Issue 1

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Biologic rationale for and efficacy and tolerability of CAR T cells targeting BCMA in MM	4 3 2 1	4 3 2 1
Activity and ongoing investigation of the anti-CD38 antibody isatuximab for R/R MM	4 3 2 1	4 3 2 1
Biologic rationales for the effectiveness of venetoclax in patients with MM and for the lower risk of associated tumor lysis syndrome compared to chronic lymphocytic leukemia	4 3 2 1	4 3 2 1
Safety and effectiveness of subcutaneous daratumumab	4 3 2 1	4 3 2 1
Emerging research data with and nonresearch role, if any, of ixazomib as a component of induction and maintenance therapy	4 3 2 1	4 3 2 1

Practice Setting:

⬭ Academic center/medical school ⬭ Community cancer center/hospital ⬭ Group practice

⬭ Solo practice ⬭ Government (eg, VA) ⬭ Other (please specify).....

Approximately how many new patients with multiple myeloma do you see per year? ..... patients

Was the activity evidence based, fair, balanced and free from commercial bias?

⬭ Yes ⬭ No If no, please explain: .....

Please identify how you will change your practice as a result of completing this activity (select all that apply).

⬭ This activity validated my current practice

⬭ Create/revise protocols, policies and/or procedures

⬭ Change the management and/or treatment of my patients

⬭ Other (please explain): .....

If you intend to implement any changes in your practice, please provide 1 or more examples:

.....

.....

The content of this activity matched my current (or potential) scope of practice.

⬭ Yes ⬭ No If no, please explain: .....

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Use patient and disease characteristics, including cytogenetic profile, to customize induction and maintenance therapeutic approaches in the transplant and nontransplant settings. . . . . 4 3 2 1 N/M N/A
- Consider available research data and other clinical factors in the best-practice selection, sequencing and combination of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory MM. . . . . 4 3 2 1 N/M N/A
- Design and implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies to support quality of life and continuation of treatment. . . . . 4 3 2 1 N/M N/A
- Develop an evidence-based algorithm for the use of stem cell transplantation, chemotherapy and/or novel targeted agents for the management of amyloidosis. . . . . 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

As a result of this activity, I will be able to:

- Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for WM requiring active treatment. . . . . 4 3 2 1 N/M N/A
- Develop risk-adapted treatment plans for patients with smoldering MM, considering the roles of observation and active treatment. . . . . 4 3 2 1 N/M N/A

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

. . . . . .

. . . . . .

Would you recommend this activity to a colleague?

☐ Yes ☐ No

If no, please explain: . . . . . .

PART 2 — Please tell us about the faculty and editor for this educational activity

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

Faculty	Knowledge of subject matter	Effectiveness as an educator
Edward A Stadtmauer, MD	4 3 2 1	4 3 2 1
Sarah A Holstein, MD, PhD	4 3 2 1	4 3 2 1
Paul G Richardson, MD	4 3 2 1	4 3 2 1
Shaji K Kumar, MD	4 3 2 1	4 3 2 1
Editor	**Knowledge of subject matter**	**Effectiveness as an educator**
Neil Love, MD	4 3 2 1	4 3 2 1

Please recommend additional faculty for future activities:

. . . . . .

. . . . . .

REQUEST FOR CREDIT — Please print clearly

Name: . . . . . Specialty: . . . . . .

Professional Designation:

☐ MD ☐ DO ☐ PharmD ☐ NP ☐ RN ☐ PA ☐ Other: . . . . . .

Street Address: . . . . . Box/Suite: . . . . . .

City, State, Zip: . . . . . .

Telephone: . . . . . Fax: . . . . . .

Email: . . . . . .

Penn State College of Medicine designates this enduring material for a maximum of 4.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: . . . . . Date: . . . . . .

The expiration date for this activity is February 1, 2019. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/MMUpdate118/CME.

QID 1877

Multiple Myeloma™ UPDATE

PRSRT STD
U.S. POSTAGE
PAID
MIAMI, FL
PERMIT #1317

Neil Love, MD
Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.

Research To Practice®

PennState College of Medicine

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Release date: February 1, 2018
Expiration date: February 1, 2019
Estimated time to complete: 4.5 hours